ABEO · XBRL financial data

Abeona Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ABEO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	10,000	3,000	1,414	3,500	—	5,820
Cost of goods and services sold	—	—	—	—	—	1,532
Research and development	30,139	34,325	28,965	31,091	34,360	26,812
Selling, general and administrative	—	—	—	—	29,851	65,031
General and administrative	23,779	22,795	17,256	19,004	29,851	65,031
Total operating expenses	91,420	92,836	52,329	50,635	64,211	—
Operating income (loss)	(81,420)	(89,836)	(50,915)	(47,135)	(64,211)	(89,448)
Interest expense	4,115	3,670	736	418	4,208	3,740
Income tax expense (benefit)	—	—	—	—	—	100
Net income (loss)	(84,234)	(84,936)	(39,696)	(54,188)	(63,734)	71,183
Earnings per share, basic USD per share	—	(21.57)	(5.53)	(2.53)	(1.55)	1.34
Earnings per share, diluted USD per share	—	—	(5.53)	(2.53)	(1.55)	1.01
Weighted average shares, basic thousands of shares	—	3,938	7,862	21,380	41,048	52,953
Weighted average shares, diluted thousands of shares	—	—	7,862	21,380	41,048	66,136

Fiscal years (ABEO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	12,596	32,938	14,217	14,473	23,357	78,437
Short-term investments	82,438	12,086	37,932	37,753	74,363	112,967
Accounts receivable	—	3,000	—	—	—	6,147
Inventory	—	—	—	—	—	5,493
Prepaid and other current assets	2,708	7,377	424	729	1,143	1,294
Total current assets	97,742	55,401	53,099	55,737	100,853	204,906
Property and equipment, net	11,322	12,339	5,741	3,533	4,430	9,921
Right-of-use asset	7,032	9,403	5,331	4,455	3,552	3,962
Goodwill	32,466	—	—	—	—	—
Total assets	151,198	79,586	64,214	64,002	108,931	219,570
Accounts payable	4,695	4,325	1,811	1,858	3,441	7,889
Accrued liabilities	3,410	5,585	3,991	5,985	6,333	8,467
Current portion of long-term debt	—	—	—	—	5,926	12,222
Total current liabilities	41,959	16,623	7,779	13,422	16,587	29,570
Long-term debt	—	—	—	—	13,037	7,813
Lease liability, non-current	5,260	7,560	5,854	4,402	3,262	4,069
Total liabilities	48,647	28,211	37,453	49,176	64,900	60,354
Accumulated deficit	(570,704)	(655,640)	(695,336)	(749,524)	(813,258)	(742,075)
Total stockholders' equity	102,551	51,375	26,761	14,826	44,031	159,216
Total liabilities and equity	151,198	79,586	64,214	64,002	108,931	219,570
Common shares outstanding (cover page) thousands of shares	98,789	147,378	17,709	27,355	48,534	57,049

Fiscal years (ABEO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(84,234)	(84,936)	(39,696)	(54,188)	(63,734)	71,183
Stock-based compensation	—	—	3,051	4,768	6,628	10,779
Depreciation and amortization	4,586	3,250	3,093	2,288	2,004	2,549
Net cash from operating activities	(35,019)	(65,665)	(43,483)	(37,009)	(56,015)	(76,326)
Purchases of property and equipment	1,336	4,151	130	331	2,446	7,975
Net cash from investing activities	(83,714)	66,062	(23,964)	208	(39,240)	105,028
Proceeds from issuing common stock	—	8,051	12,839	14,408	15,475	17,300
Proceeds from issuing equity	—	—	—	—	4,800	—
Proceeds from long-term debt	—	—	—	—	20,000	—
Net cash from financing activities	1,936	24,861	43,173	37,057	104,139	26,040
Net change in cash	(116,797)	25,258	(24,274)	256	8,884	54,742

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Ocugen	24,632	1,951	not reported	339.3M	—	Q3 FY26 10-QSep 30, 2026
Mersana Therapeutics	56,391	11,009	(3,192)*	5.0M	17.7 quarters	Q3 FY25 10-QSep 30, 2025
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Standard Biotools	267,487	19,385	(6,161)*	394.8M	21.6 quarters	Q3 FY26 10-QSep 30, 2026
Aquestive Therapeutics	90,349	7,557	(7,046)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Merus	367,491	12,150	(84,917)*	75.8M	7.5 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.